Angiotensin-converting enzyme 2 protects from lethal a

Nature Communications

5, 3594

DOI: 10.1038/ncomms4594

Citation Report

#	Article	IF	Citations
1	Angiotensin II plasma levels are linked to disease severity and predict fatal outcomes in H7N9-infected patients. Nature Communications, 2014, 5, 3595.	5.8	137
2	Oral Delivery of Angiotensin-Converting Enzyme 2 and Angiotensin-(1-7) Bioencapsulated in Plant Cells Attenuates Pulmonary Hypertension. Hypertension, 2014, 64, 1248-1259.	1.3	126
3	Angiotensin-converting enzyme 2 (ACE2) mediates influenza H7N9 virus-induced acute lung injury. Scientific Reports, 2014, 4, 7027.	1.6	249
4	ACE2 and Microbiota. Journal of Cardiovascular Pharmacology, 2015, 66, 540-550.	0.8	94
5	The Serum Profile of Hypercytokinemia Factors Identified in H7N9-Infected Patients can Predict Fatal Outcomes. Scientific Reports, 2015, 5, 10942.	1.6	93
6	Efficacy of coupled low-volume plasma exchange with plasma filtration adsorption in treating pigs with acute liver failure: A randomised study. Journal of Hepatology, 2015, 63, 378-387.	1.8	33
7	Angiotensin II receptor blocker as a novel therapy in acute lung injury induced by avian influenza A H5N1 virus infection in mouse. Science China Life Sciences, 2015, 58, 208-211.	2.3	40
8	Novel RAAS agonists and antagonists: clinical applications and controversies. Nature Reviews Endocrinology, 2015, 11, 242-252.	4.3	126
9	Cationic nanoparticles directly bind angiotensin-converting enzyme 2 and induce acute lung injury in mice. Particle and Fibre Toxicology, 2015, 12, 4.	2.8	44
10	Influenza virus-induced lung injury: pathogenesis and implications for treatment. European Respiratory Journal, 2015, 45, 1463-1478.	3.1	355
11	Hyperoxia downregulates angiotensin-converting enzyme-2 in human fetal lung fibroblasts. Pediatric Research, 2015, 77, 656-662.	1.1	45
12	Neuraminidase of Influenza A Virus Binds Lysosome-Associated Membrane Proteins Directly and Induces Lysosome Rupture. Journal of Virology, 2015, 89, 10347-10358.	1.5	42
13	Nonstructural Protein 1 (NS1)-Mediated Inhibition of c-Abl Results in Acute Lung Injury and Priming for Bacterial Co-infections: Insights Into 1918 H1N1 Pandemic?. Journal of Infectious Diseases, 2015, 211, 1418-1428.	1.9	14
14	Pulmonary Angiotensin-Converting Enzyme 2 (ACE2) and Inflammatory Lung Disease. Shock, 2016, 46, 239-248.	1.0	259
15	Angiotensin-converting enzyme 2 prevents lipopolysaccharide-induced rat acute lung injury via suppressing the ERK1/2 and NF-Î¹B signaling pathways. Scientific Reports, 2016, 6, 27911.	1.6	135
16	Association of the Serum Angiotensin II Level with Disease Severity in Severe Fever with Thrombocytopenia Syndrome Patients. Internal Medicine, 2016, 55, 895-900.	0.3	4
17	The pulmonary endothelium in acute respiratory distress syndrome: insights and therapeutic opportunities. Thorax, 2016, 71, 462-473.	2.7	169
18	Human Influenza Virus Infections. Seminars in Respiratory and Critical Care Medicine, 2016, 37, 487-500.	0.8	154

#	Article	IF	Citations
19	Angiotensin-converting enzyme 2 inhibits lung injury induced by respiratory syncytial virus. Scientific Reports, 2016, 6, 19840.	1.6	202
20	Angiotensin-converting enzyme 2 is a potential therapeutic target for EGFR -mutant lung adenocarcinoma. Biochemical and Biophysical Research Communications, 2017, 487, 613-618.	1.0	15
21	LAMP-2 mediates oxidative stress-dependent cell death in Zn 2+ -treated lung epithelium cells. Biochemical and Biophysical Research Communications, 2017, 488, 177-181.	1.0	24
22	Protein Malnutrition Alters Tryptophan and Angiotensin-Converting Enzyme 2 Homeostasis and Adaptive Immune Responses in Human Rotavirus-Infected Gnotobiotic Pigs with Human Infant Fecal Microbiota Transplant. Vaccine Journal, 2017, 24, .	3.2	30
23	miRNA-200c-3p is crucial in acute respiratory distress syndrome. Cell Discovery, 2017, 3, 17021.	3.1	95
24	Serum Metabolic Alterations upon Zika Infection. Frontiers in Microbiology, 2017, 8, 1954.	1.5	36
25	A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome. Critical Care, 2017, 21, 234.	2.5	515
26	Recombinant human ACE2: acing out angiotensin II in ARDS therapy. Critical Care, 2017, 21, 305.	2.5	153
27	The evolving role of the reninâ€“angiotensin system in ARDS. Critical Care, 2017, 21, 329.	2.5	9
28	Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: A Promising Medication for Chronic Obstructive Pulmonary Disease?. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2018, 15, 148-156.	0.7	23
29	The size of zinc oxide nanoparticles controls its toxicity through impairing autophagic flux in A549 lung epithelial cells. Toxicology Letters, 2018, 285, 51-59.	0.4	52
30	Novel ACE2-Fc chimeric fusion provides long-lasting hypertension control and organ protection in mouse models of systemic renin angiotensin system activation. Kidney International, 2018, 94, 114-125.	2.6	94
31	Attenuation of pulmonary ACE2 activity impairs inactivation of des-Arg⁹bradykinin/BKB1R axis and facilitates LPS-induced neutrophil infiltration. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2018, 314, L17-L31.	1.3	304
32	The acute respiratory distress syndrome: pathophysiology, current clinical practice, and emerging therapies. Expert Review of Respiratory Medicine, 2018, 12, 1021-1029.	1.0	42
33	Î³Î´ T Cells Provide Protective Function in Highly Pathogenic Avian H5N1 Influenza A Virus Infection. Frontiers in Immunology, 2018, 9, 2812.	2.2	31
34	Involvement of the renin-angiotensin system in the progression of severe hand-foot-and-mouth disease. PLoS ONE, 2018, 13, e0197861.	1.1	8
35	The ACE2/Angiotensin-(1â€“7)/MAS Axis of the Renin-Angiotensin System: Focus on Angiotensin-(1â€“7). Physiological Reviews, 2018, 98, 505-553.	13.1	756
36	Renin-angiotensin-system, a potential pharmacological candidate, in acute respiratory distress syndrome during mechanical ventilation. Pulmonary Pharmacology and Therapeutics, 2019, 58, 101833.	1.1	58

#	Article	IF	Citations
37	Immune function of an angiotensin-converting enzyme against Rice stripe virus infection in a vector insect. Virology, 2019, 533, 137-144.	1.1	6
38	Sini decoction ameliorates sepsis-induced acute lung injury via regulating ACE2-Ang (1-7)-Mas axis and inhibiting the MAPK signaling pathway. Biomedicine and Pharmacotherapy, 2019, 115, 108971.	2.5	35
39	Ifenprodil and Flavopiridol Identified by Genomewide RNA Interference Screening as Effective Drugs To Ameliorate Murine Acute Lung Injury after Influenza A H5N1 Virus Infection. MSystems, 2019, 4, .	1.7	12
40	A Dynamic Variation of Pulmonary ACE2 Is Required to Modulate Neutrophilic Inflammation in Response to Pseudomonas aeruginosa Lung Infection in Mice. Journal of Immunology, 2019, 203, 3000-3012.	0.4	94
41	Development and validation of an LC-MS/MS method for detection and quantification of in vivo derived metabolites of [Pyr1]apelin-13 in humans. Scientific Reports, 2019, 9, 19934.	1.6	14
42	Renin-angiotensin system blockers and severe acute respiratory syndrome coronavirus 2. Archives of Cardiovascular Diseases, 2020, 113, 572-578.	0.7	2
43	Deadly Companions: COVID-19 and Diabetes in Mexico. Medical Anthropology: Cross Cultural Studies in Health and Illness, 2020, 39, 660-665.	0.6	19
44	ACE2/ADAM17/TMPRSS2 Interplay May Be the Main Risk Factor for COVID-19. Frontiers in Immunology, 2020, 11, 576745.	2.2	187
45	Male predisposition to severe COVID-19: Review of evidence and potential therapeutic prospects. Biomedicine and Pharmacotherapy, 2020, 131, 110748.	2.5	30
46	On the genetics and immunopathogenesis of COVID-19. Clinical Immunology, 2020, 220, 108591.	1.4	32
47	Should ACE2 be given a chance in COVID-19 therapeutics: A semi-systematic review of strategies enhancing ACE2. European Journal of Pharmacology, 2020, 887, 173545.	1.7	30
48	ACEIs and ARBs and Their Correlation with COVID-19: A Review . Infection and Drug Resistance, 2020, Volume 13, 3217-3224.	1.1	23
49	ACE2 mouse models: a toolbox for cardiovascular and pulmonary research. Nature Communications, 2020, 11, 5165.	5.8	51
50	Interferons and viruses induce a novel truncated ACE2 isoform and not the full-length SARS-CoV-2 receptor. Nature Genetics, 2020, 52, 1283-1293.	9.4	217
51	Unraveling the Role of ACE2, the Binding Receptor for SARS-CoV-2, in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2020, 26, 1787-1795.	0.9	12
52	The Possible Dual Role of the ACE2 Receptor in Asthma and Coronavirus (SARS-CoV2) Infection. Frontiers in Cellular and Infection Microbiology, 2020, 10, 550571.	1.8	24
53	Repurposing existing drugs for COVID-19: an endocrinology perspective. BMC Endocrine Disorders, 2020, 20, 149.	0.9	36
54	Heterogeneous expression of the SARS-Coronavirus-2 receptor ACE2 in the human respiratory tract. EBioMedicine, 2020, 60, 102976.	2.7	153

#	Article	IF	Citations
55	Obesity, Diabetes and COVID-19: An Infectious Disease Spreading From the East Collides With the Consequences of an Unhealthy Western Lifestyle. Frontiers in Endocrinology, 2020, 11, 582870.	1.5	43
56	Angiotensinâ€converting enzyme inhibitor/angiotensin II receptor blocker treatment and haemodynamic factors are associated with increased cardiac mRNA expression of angiotensinâ€converting enzyme 2 in patients with cardiovascular disease. European Journal of Heart Failure, 2020, 22, 2248-2257.	2.9	13
58	New insights on possible vaccine development against SARS-CoV-2. Life Sciences, 2020, 260, 118421.	2.0	8
59	SARS-CoV2 coronavirus: so far polite with children. Debatable immunological and non-immunological evidence. Allergologia Et Immunopathologia, 2020, 48, 500-506.	1.0	3
60	Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19. Critical Care, 2020, 24, 422.	2.5	768
61	Intoxication With Endogenous Angiotensin II: A COVID-19 Hypothesis. Frontiers in Immunology, 2020, 11, 1472.	2.2	38
62	Particulate matter (PM10) enhances RNA virus infection through modulation of innate immune responses. Environmental Pollution, 2020, 266, 115148.	3.7	39
63	The dual impact of ACE2 in COVID-19 and ironical actions in geriatrics and pediatrics with possible therapeutic solutions. Life Sciences, 2020, 257, 118075.	2.0	87
64	Lessons for COVID-19 Immunity from Other Coronavirus Infections. Immunity, 2020, 53, 248-263.	6.6	281
65	SARS-CoV-2, ACE2, and Hydroxychloroquine: Cardiovascular Complications, Therapeutics, and Clinical Readouts in the Current Settings. Pathogens, 2020, 9, 546.	1.2	31
66	Cardiovascular Disease and SARS-CoV-2: the Role of Host Immune Response Versus Direct Viral Injury. International Journal of Molecular Sciences, 2020, 21, 8141.	1.8	4
67	Impact of SARS-CoV-2 on Male Reproductive Health: A Review of the Literature on Male Reproductive Involvement in COVID-19. Frontiers in Medicine, 2020, 7, 594364.	1.2	22
68	Endothelial Damage in Acute Respiratory Distress Syndrome. International Journal of Molecular Sciences, 2020, 21, 8793.	1.8	110
69	The potential role of serum angiotensin-converting enzyme in coronavirus disease 2019. BMC Infectious Diseases, 2020, 20, 883.	1.3	23
70	MANAGEMENT OF DIABETES WITH COVID-19: A REVIEW. International Journal of Pharmacy and Pharmaceutical Sciences, 0, , 1-6.	0.3	7
71	Patients taking angiotensin-converting enzyme inhibitors/angiotensin II type I receptor blockers: higher risks of severe acute respiratory syndrome coronavirus 2 infection but milder clinical manifestations?. Chinese Medical Journal, 2020, 133, 2650-2652.	0.9	2
72	COVID-19 and the Kidney: From Epidemiology to Clinical Practice. Journal of Clinical Medicine, 2020, 9, 2506.	1.0	72
73	While We Wait for a Vaccine Against SARS-CoV-2, Why Not Think About Available Drugs?. Frontiers in Physiology, 2020, 11, 820.	1.3	13

#	Article	IF	Citations
74	Very low reporting rate of connective tissue diseases among coronavirus disease 2019 (Covid-19) patients and the renin-angiotensin system â€“ An overlooked association?. European Journal of Internal Medicine, 2020, 80, 106-107.	1.0	1
75	Design of an engineered ACE2 as a novel therapeutics against COVID-19. Journal of Theoretical Biology, 2020, 505, 110425.	0.8	13
76	The Effects of Chloroquine and Hydroxychloroquine on ACE2-Related Coronavirus Pathology and the Cardiovascular System: An Evidence-Based Review. Function, 2020, 1, .	1.1	12
77	Role of comorbidities like diabetes on severe acute respiratory syndrome coronavirus-2: A review. Life Sciences, 2020, 258, 118202.	2.0	43
78	Spironolactone may provide protection from SARS-CoV-2: Targeting androgens, angiotensin converting enzyme 2 (ACE2), and renin-angiotensin-aldosterone system (RAAS). Medical Hypotheses, 2020, 143, 110112.	0.8	45
79	Delineating clinical characteristics and comorbidities among 206 COVID-19 deceased patients in India: Emerging significance of renin angiotensin system derangement. Diabetes Research and Clinical Practice, 2020, 167, 108349.	1.1	11
80	Role of the renin-angiotensin system in the development of severe COVID-19 in hypertensive patients. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2020, 319, L596-L602.	1.3	14
81	ACE2, COVID-19 Infection, Inflammation, and Coagulopathy: Missing Pieces in the Puzzle. Frontiers in Physiology, 2020, 11, 574753.	1.3	54
82	Reninâ€“Angiotensin System: An Important Player in the Pathogenesis of Acute Respiratory Distress Syndrome. International Journal of Molecular Sciences, 2020, 21, 8038.	1.8	50
83	Role of Renin-Angiotensin System in Acute Lung Injury Caused by Viral Infection . Infection and Drug Resistance, 2020, Volume 13, 3715-3725.	1.1	33
84	ACE2 in the Era of SARS-CoV-2: Controversies and Novel Perspectives. Frontiers in Molecular Biosciences, 2020, 7, 588618.	1.6	77
85	Cardiovascular Manifestations and Mechanisms in Patients with COVID-19. Trends in Endocrinology and Metabolism, 2020, 31, 893-904.	3.1	49
86	The reninâ€“angiotensin system: An integrated view of lung disease and coagulopathy in COVID-19 and therapeutic implications. Journal of Experimental Medicine, 2020, 217, .	4.2	21
87	Antihypertensive drugs are associated with reduced fatal outcomes and improved clinical characteristics in elderly COVID-19 patients. Cell Discovery, 2020, 6, 77.	3.1	54
88	Clinical Characteristics of Patients with Severe Pneumonia Caused by the SARS-CoV-2 in Wuhan, China. Respiration, 2020, 99, 649-657.	1.2	28
89	Insight View on Pandemic COVID-19: Worldwide Perspective with Homoeopathic Management through Repertorial Analysis. Homopathic Links, 2020, 33, 180-195.	0.1	3
90	Human recombinant soluble ACE2 in severe COVID-19. Lancet Respiratory Medicine,the, 2020, 8, 1154-1158.	5.2	340
91	Renin-Angiotensin System and Coronavirus Disease 2019: A Narrative Review. Frontiers in Cardiovascular Medicine, 2020, 7, 143.	1.1	35

#	Article	IF	Citations
92	Interaction of SARS-CoV-2 and Other Coronavirus With ACE (Angiotensin-Converting Enzyme)-2 as Their Main Receptor. Hypertension, 2020, 76, 1339-1349.	1.3	147
93	No small matter: a perspective on nanotechnology-enabled solutions to fight COVID-19. Nanomedicine, 2020, 15, 2411-2427.	1.7	19
94	ACE2 (Angiotensin-Converting Enzyme 2) in Cardiopulmonary Diseases. Hypertension, 2020, 76, 651-661.	1.3	57
95	Reninâ€“angiotensin system inhibitors and the severity of coronavirus disease 2019 in Kanagawa, Japan: a retrospective cohort study. Hypertension Research, 2020, 43, 1257-1266.	1.5	43
96	A potential hypothesis for 2019-nCoV infection therapy through delivery of recombinant ACE2 by red blood cell-hitchhiking. Journal of Biological Research, 2020, 27, .	2.2	1
97	Pathophysiology of SARS-CoV-2 in Lung of Diabetic Patients. Frontiers in Physiology, 2020, 11, 587013.	1.3	12
98	The outcomes of the postulated interaction between SARS-CoV-2 and the renin-angiotensin system on the clinicianâ€™s attitudes toward hypertension treatment. Journal of Human Hypertension, 2020, 35, 828-836.	1.0	1
99	miR-98 Regulates TMPRSS2 Expression in Human Endothelial Cells: Key Implications for COVID-19. Biomedicines, 2020, 8, 462.	1.4	103
100	A current review of COVID-19 for the cardiovascular specialist. American Heart Journal, 2020, 226, 29-44.	1.2	97
101	Reflection on lower rates of COVID-19 in children: Does childhood immunizations offer unexpected protection?. Medical Hypotheses, 2020, 143, 109842.	0.8	30
102	Potential differential effects of renin-angiotensin system inhibitors on SARS-CoV-2 infection and lung injury in COVID-19. Hypertension Research, 2020, 43, 837-840.	1.5	32
103	Management of Osteoarthritis During the COVIDâ€19 Pandemic. Clinical Pharmacology and Therapeutics, 2020, 108, 719-729.	2.3	17
104	The role of vitamin D in the prevention of coronavirus disease 2019 infection and mortality. Aging Clinical and Experimental Research, 2020, 32, 1195-1198.	1.4	584
105	Coronavirus disease 2019 (COVID-19) and the renin-angiotensin system: A closer look at angiotensin-converting enzyme 2 (ACE2). Annals of Clinical Biochemistry, 2020, 57, 339-350.	0.8	29
106	COVID-19 and diabetes mellitus: An unholy interaction of two pandemics. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2020, 14, 513-517.	1.8	190
107	Hypertension, Thrombosis, Kidney Failure, and Diabetes: Is COVID-19 an Endothelial Disease? A Comprehensive Evaluation of Clinical and Basic Evidence. Journal of Clinical Medicine, 2020, 9, 1417.	1.0	411
108	Protective role of ACE2 and its downregulation in SARS-CoV-2 infection leading to Macrophage Activation Syndrome: Therapeutic implications. Life Sciences, 2020, 256, 117905.	2.0	138
109	Pathophysiology of COVID-19: Why Children Fare Better than Adults?. Indian Journal of Pediatrics, 2020, 87, 537-546.	0.3	237

#	Article	IF	Citations
110	Use of reninâ€“angiotensinâ€“aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study. Lancet, The, 2020, 395, 1705-1714.	6.3	347
111	COVID-19, chronic inflammatory rheumatic disease and anti-rheumatic treatments. Clinical Rheumatology, 2020, 39, 2069-2075.	1.0	29
112	Diabetes and metabolic syndrome as risk factors for COVID-19. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2020, 14, 671-677.	1.8	59
113	Coronavirus Disease 2019 (COVID-19) and its implications for cardiovascular care: expert document from the German Cardiac Society and the World Heart Federation. Clinical Research in Cardiology, 2020, 109, 1446-1459.	1.5	51
114	Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and coronavirus. Journal of Hypertension, 2020, 38, 1190-1191.	0.3	25
115	Aspectos y consideraciones generales en la enfermedad inflamatoria intestinal durante la pandemia por COVID-19. Revista De GastroenterologÃa De MÃ©xico, 2020, 85, 295-302.	0.4	10
116	Possible therapeutic agents for COVID-19: a comprehensive review. Expert Review of Anti-Infective Therapy, 2020, 18, 1005-1020.	2.0	24
117	The reninâ€“angiotensinâ€“aldosterone system as a link between obesity and coronavirus disease 2019 severity. Obesity Reviews, 2020, 21, e13077.	3.1	27
118	COVID-19 and comorbidities: a systematic review and meta-analysis. Postgraduate Medicine, 2020, 132, 749-755.	0.9	195
119	Targeting SARS-CoV-2 receptors as a means for reducing infectivity and improving antiviral and immune response: an algorithm-based method for overcoming resistance to antiviral agents. Emerging Microbes and Infections, 2020, 9, 1397-1406.	3.0	49
120	Biomarkers associated with COVID-19 disease progression. Critical Reviews in Clinical Laboratory Sciences, 2020, 57, 389-399.	2.7	570
121	Acute lung injury in patients with COVIDâ€19 infection. Clinical and Translational Medicine, 2020, 10, 20-27.	1.7	88
122	Potential Role of Anti-interleukin (IL)-6 Drugs in the Treatment of COVID-19: Rationale, Clinical Evidence and Risks. BioDrugs, 2020, 34, 415-422.	2.2	50
123	Individual variation of the SARSâ€CoVâ€2 receptor ACE2 gene expression and regulation. Aging Cell, 2020, 19, e13168.	3.0	343
124	Localization of Cell Receptor-Related Genes of SARS-CoV-2 in the Kidney through Single-Cell Transcriptome Analysis. Kidney Diseases (Basel, Switzerland), 2020, 6, 258-270.	1.2	19
125	Identification of amitriptyline HCl, flavin adenine dinucleotide, azacitidine and calcitriol as repurposing drugs for influenza A H5N1 virus-induced lung injury. PLoS Pathogens, 2020, 16, e1008341.	2.1	65
126	COVID-19 infection and rheumatoid arthritis: Faraway, so close!. Autoimmunity Reviews, 2020, 19, 102523.	2.5	353
127	Should COVID-19 Concern Nephrologists? Why and to What Extent? The Emerging Impasse of Angiotensin Blockade. Nephron, 2020, 144, 213-221.	0.9	245

#	Article	IF	Citations
128	Antihypertensive drugs and risk of COVID-19?. Lancet Respiratory Medicine,the, 2020, 8, e30-e31.	5.2	74
129	Reninâ€“Angiotensinâ€“Aldosterone System Inhibitors in Patients with Covid-19. New England Journal of Medicine, 2020, 382, 1653-1659.	13.9	1,732
130	Pathological Role of Angiotensin II in Severe COVID-19. TH Open, 2020, 04, e138-e144.	0.7	87
131	Update on therapeutic approaches and emerging therapies for SARS-CoV-2 virus. European Journal of Pharmacology, 2020, 883, 173348.	1.7	55
132	Disequilibrium between the classic renin-angiotensin system and its opposing arm in SARS-CoV-2-related lung injury. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2020, 319, L325-L336.	1.3	69
133	The Impact of COVID-19 on Cancer Risk and Treatment. Cellular and Molecular Bioengineering, 2020, 13, 285-291.	1.0	33
134	Obesity, the most common comorbidity in SARS-CoV-2: is leptin the link?. International Journal of Obesity, 2020, 44, 1810-1817.	1.6	72
135	Angiotensin <scp>II</scp> receptors: Impact for <scp>COVID</scp> â€19 severity. Dermatologic Therapy, 2020, 33, e13989.	0.8	33
136	Aspects of inflammatory bowel disease during the COVID-19 pandemic and general considerations. Revista De GastroenterologÃa De MÃ©xico (English Edition), 2020, 85, 295-302.	0.1	8
137	Recombinant human ACE2: potential therapeutics of SARS-CoV-2 infection and its complication. Acta Pharmacologica Sinica, 2020, 41, 1255-1257.	2.8	50
138	ACE2 as a Therapeutic Target for COVID-19; Its Role in Infectious Processes and Regulation by Modulators of the RAAS System. Journal of Clinical Medicine, 2020, 9, 2096.	1.0	27
139	Diabetes and COVID-19: Global and regional perspectives. Diabetes Research and Clinical Practice, 2020, 166, 108303.	1.1	43
140	COVID-19 and Avoiding Ibuprofen. How Good Is the Evidence?. American Journal of Therapeutics, 2020, 27, e400-e402.	0.5	28
141	Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Science China Life Sciences, 2020, 63, 364-374.	2.3	1,606
142	On Facing the SARS-CoV-2 (COVID-19) with Combination of Nanomaterials and Medicine: Possible Strategies and First Challenges. Nanomaterials, 2020, 10, 852.	1.9	102
143	COVID-19 and RAS: Unravelling an Unclear Relationship. International Journal of Molecular Sciences, 2020, 21, 3003.	1.8	75
144	Quantitative computed tomography of the coronavirus disease 2019 (COVID-19) pneumonia. Radiology of Infectious Diseases, 2020, 7, 55-61.	2.4	37
145	SARS-CoV-2 receptor ACE2-dependent implications on the cardiovascular system: From basic science to clinical implications. Journal of Molecular and Cellular Cardiology, 2020, 144, 47-53.	0.9	111

#	Article	IF	Citations
146	Understanding the reninâ€“angiotensinâ€“aldosteroneâ€“SARS-CoV axis: a comprehensive review. European Respiratory Journal, 2020, 56, 2000912.	3.1	123
147	COVID-19 for the Cardiologist. JACC Basic To Translational Science, 2020, 5, 518-536.	1.9	256
149	COVID-19, diabetes mellitus and ACE2: The conundrum. Diabetes Research and Clinical Practice, 2020, 162, 108132.	1.1	267
150	The role of angiotensin-converting enzyme 2 in coronaviruses/influenza viruses and cardiovascular disease. Cardiovascular Research, 2020, 116, 1932-1936.	1.8	60
151	COVIDâ€19: Risk groups, mechanistic insights and challenges. International Journal of Clinical Practice, 2020, 74, e13512.	0.8	21
152	Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig. Nature Communications, 2020, 11, 2070.	5.8	358
153	SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues. Cell, 2020, 181, 1016-1035.e19.	13.5	1,956
154	Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitorsâ€”lessons from available evidence and insights into COVID-19. Hypertension Research, 2020, 43, 648-654.	1.5	330
155	Angiotensinâ€converting enzyme 2 in severe acute respiratory syndrome coronavirus and SARSâ€CoVâ€2: A doubleâ€edged sword?. FASEB Journal, 2020, 34, 6017-6026.	0.2	90
156	Hypertension, the reninâ€“angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19. Cardiovascular Research, 2020, 116, 1688-1699.	1.8	282
157	ACEing COVID-19. Circulation Research, 2020, 126, 1682-1684.	2.0	9
158	Emergence of Novel Coronavirus and COVID-19: whether to stay or die out?. Critical Reviews in Microbiology, 2020, 46, 182-193.	2.7	99
159	An update on ACE2 amplification and its therapeutic potential. Acta Physiologica, 2021, 231, e13513.	1.8	33
160	Mechanisms of COVIDâ€19â€induced cardiovascular disease:ÂIs sepsis or exosome the missing link?. Journal of Cellular Physiology, 2021, 236, 3366-3382.	2.0	21
161	Angiotensin-converting enzyme 2 (ACE2): SARS-CoV-2 receptor and RAS modulator. Acta Pharmaceutica Sinica B, 2021, 11, 1-12.	5.7	93
162	A comprehensive guide to the pharmacologic regulation of angiotensin converting enzyme 2 (ACE2), the SARS-CoV-2 entry receptor. , 2021, 221, 107750.		34
163	Why is COVID-19 less severe in children? A review of the proposed mechanisms underlying the age-related difference in severity of SARS-CoV-2 infections. Archives of Disease in Childhood, 2021, 106, 429-439.	1.0	374
164	Angiotensin-converting enzyme 2 and COVID-19: patients, comorbidities, and therapies. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2021, 320, L301-L330.	1.3	26

#	Article	IF	Citations
165	ACE inhibitors, angiotensin receptor blockers and endothelial injury in COVIDâ€19. Journal of Internal Medicine, 2021, 289, 688-699.	2.7	26
166	Development of Plant-Produced Recombinant ACE2-Fc Fusion Protein as a Potential Therapeutic Agent Against SARS-CoV-2. Frontiers in Plant Science, 2020, 11, 604663.	1.7	37
167	The Counter Regulatory Axis of the Lung Renin-Angiotensin System in Severe COVID-19: Pathophysiology and Clinical Implications. Heart Lung and Circulation, 2021, 30, 786-794.	0.2	16
168	Could SARS-CoV-2-induced lung injury be attenuated by vitamin D?. International Journal of Infectious Diseases, 2021, 102, 196-202.	1.5	20
169	Gender susceptibility to COVID-19: a review of the putative role of sex hormones and X chromosome. Journal of Endocrinological Investigation, 2021, 44, 951-956.	1.8	79
170	Pulmonary fibrosing diseases: A short review and a therapeutic alternative. GSC Biological and Pharmaceutical Sciences, 2021, 14, 137-148.	0.1	0
171	A Potential Role of the Renin-Angiotensin-System for Disturbances of Respiratory Chemosensitivity in Acute Respiratory Distress Syndrome and Severe Acute Respiratory Syndrome. Frontiers in Physiology, 2020, 11, 588248.	1.3	6
172	Use of non-steroidal anti-inflammatory drugs and risk of death from COVID-19: an OpenSAFELY cohort analysis based on two cohorts. Annals of the Rheumatic Diseases, 2021, 80, 943-951.	0.5	66
173	COVID-19, Angiotensin-Converting Enzyme 2 and Renin-Angiotensin System Inhibition: Implications for Practice. Current Hypertension Reviews, 2021, 17, .	0.5	2
174	Does Angiotensin II Peak in Response to SARS-CoV-2?. Frontiers in Immunology, 2020, 11, 577875.	2.2	11
175	The controversy of using angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in COVID-19 patients. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2021, 22, 147032032098711.	1.0	6
176	Influenza virus infection increases ACE2 expression and shedding in human small airway epithelial cells. European Respiratory Journal, 2021, 58, 2003988.	3.1	38
177	Clinical Manifestations of Cytokine Storm and Immune Response to COVID-19: Literature Review. Open Journal of Internal Medicine, 2021, 11, 151-174.	0.1	0
178	A trimeric human angiotensin-converting enzyme 2 as an anti-SARS-CoV-2 agent. Nature Structural and Molecular Biology, 2021, 28, 202-209.	3.6	110
179	The dual role of the immune system in the course of COVID-19. The fatal impact of the aging immune system. Central-European Journal of Immunology, 2021, 46, 1-9.	0.4	12
180	An Open Label Trial to Assess Safety of Losartan for Treating Worsening Respiratory Illness in COVID-19. Frontiers in Medicine, 2021, 8, 630209.	1.2	16
181	Reninâ€“angiotensin system blockade in the COVID-19 pandemic. CKJ: Clinical Kidney Journal, 2021, 14, i48-i59.	1.4	17
182	Controversial Roles of the Renin Angiotensin System and Its Modulators During the COVID-19 Pandemic. Frontiers in Physiology, 2021, 12, 624052.	1.3	12

#	Article	IF	Citations
183	Viral Infection and Cardiovascular Disease: Implications for the Molecular Basis of COVID-19 Pathogenesis. International Journal of Molecular Sciences, 2021, 22, 1659.	1.8	16
184	The Rheumatology Drugs for COVID-19 Management: Which and When?. Journal of Clinical Medicine, 2021, 10, 783.	1.0	18
185	Hypertension artÃ©rielle et COVID-19. La Presse MÃ©dicale Formation, 2021, 2, 25-32.	0.1	2
186	Acidic preconditioning reduces lipopolysaccharideâ€induced acute lung injury by upregulating the expression of angiotensinâ€converting enzymeÂ2. Experimental and Therapeutic Medicine, 2021, 21, 441.	0.8	3
187	Silence of the Lambs: The Immunological and Molecular Mechanisms of COVID-19 in Children in Comparison with Adults. Microorganisms, 2021, 9, 330.	1.6	11
188	Angiotensin-Converting Enzyme Type 2 as a Molecular Mediator for Infection of Cells with SARS-CoV and SARS-CoV-2 Viruses. Neuroscience and Behavioral Physiology, 2021, 51, 381-389.	0.2	1
189	Investigation of structural, treatment and clinical characteristics of COVID-19 along with the challenges caused by its prevalence. Infectious Disorders - Drug Targets, 2021, 21, .	0.4	0
190	Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Angiotensin-Converting Enzyme 2 Levels: A Comprehensive Analysis Based on Animal Studies. Frontiers in Pharmacology, 2021, 12, 619524.	1.6	18
191	Renal Manifestations of Covid-19: Physiology and Pathophysiology. Journal of Clinical Medicine, 2021, 10, 1216.	1.0	27
192	Use of conventional synthetic and biologic disease-modifying anti-rheumatic drugs in patients with rheumatic diseases contracting COVID-19: a single-center experience. Rheumatology International, 2021, 41, 903-909.	1.5	9
193	The Impact of Angiotensin-Converting Enzyme 2 (ACE2) Expression on the Incidence and Severity of COVID-19 Infection. Pathogens, 2021, 10, 379.	1.2	16
194	Countries with high deaths due to flu and tuberculosis demonstrate lower COVID-19 mortality: roles of vaccinations. Human Vaccines and Immunotherapeutics, 2021, 17, 2851-2862.	1.4	8
195	Pharmacological Modulators of Autophagy as a Potential Strategy for the Treatment of COVID-19. International Journal of Molecular Sciences, 2021, 22, 4067.	1.8	27
196	Multifunctional angiotensin converting enzyme 2, the SARS-CoV-2 entry receptor, and critical appraisal of its role in acute lung injury. Biomedicine and Pharmacotherapy, 2021, 136, 111193.	2.5	42
197	The Role of Renin-Angiotensin-Aldosterone System in the Heart and Lung: Focus on COVID-19. Frontiers in Pharmacology, 2021, 12, 667254.	1.6	39
198	Deep Mutational Scanning of Viral Glycoproteins and Their Host Receptors. Frontiers in Molecular Biosciences, 2021, 8, 636660.	1.6	12
199	A comprehensive evaluation of early potential risk factors for disease aggravation in patients with COVID-19. Scientific Reports, 2021, 11, 8062.	1.6	5
200	Complications of Cardiovascular Events in Patients Hospitalized with Influenza-Related Pneumonia. Infection and Drug Resistance, 2021, Volume 14, 1363-1373.	1.1	4

#	Article	IF	Citations
201	COVID-19 infection and rheumatoid arthritis: mutual outburst cytokines and remedies. Current Medical Research and Opinion, 2021, 37, 929-938.	0.9	9
202	<scp>ACE2â€based</scp> decoy receptors for <scp>SARS</scp> coronavirus 2. Proteins: Structure, Function and Bioinformatics, 2021, 89, 1065-1078.	1.5	23
203	Targeting RAGE to prevent SARS-CoV-2-mediated multiple organ failure: Hypotheses and perspectives. Life Sciences, 2021, 272, 119251.	2.0	32
204	Type 1 Diabetes Mellitus in the SARS-CoV-2 Pandemic: Oxidative Stress as a Major Pathophysiological Mechanism Linked to Adverse Clinical Outcomes. Antioxidants, 2021, 10, 752.	2.2	14
205	Immunological Aspects of SARS-CoV-2 Infection and the Putative Beneficial Role of Vitamin-D. International Journal of Molecular Sciences, 2021, 22, 5251.	1.8	43
206	ACE2 Elevation in Severe COVID-19. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 1191-1196.	2.5	84
207	Puerarin exhibits antiinflammatory properties in gunpowder smogâ€induced acute lung injury in rats via regulation of theÂreninâ€angiotensin system and the NFÎºB signaling pathway. Experimental and Therapeutic Medicine, 2021, 22, 809.	0.8	2
209	Role of the Renin-Angiotensin-Aldosterone System in Various Disease Processes: An Overview. , 0, , .		9
210	Plasma ACE2 species are differentially altered in COVIDâ€19 patients. FASEB Journal, 2021, 35, e21745.	0.2	18
211	Vitamin D supplementation and clinical outcomes in COVID-19: a systematic review and meta-analysis. Journal of Endocrinological Investigation, 2022, 45, 53-68.	1.8	84
212	An overview of some potential immunotherapeutic options against COVID-19. International Immunopharmacology, 2021, 95, 107516.	1.7	7
213	SARS-CoV-2 Spike Protein Suppresses ACE2 and Type I Interferon Expression in Primary Cells From Macaque Lung Bronchoalveolar Lavage. Frontiers in Immunology, 2021, 12, 658428.	2.2	30
214	The COVID-19 pandemic: an increased risk of rheumatoid arthritis. Future Virology, 2021, 16, 431-442.	0.9	11
215	About the Problem of Arterial Hypertension as a Risk Factor in the COVID-19 Pandemic Conditions and its Treatment (Literature Review). Lviv Clinical Bulletin, 2021, 1-2, 31-36.	0.1	0
216	Angiotensin-Converting Enzyme 2 (ACE2) as a Potential Diagnostic and Prognostic Biomarker for Chronic Inflammatory Lung Diseases. Genes, 2021, 12, 1054.	1.0	4
217	A multi-center phase II randomized clinical trial of losartan on symptomatic outpatients with COVID-19. EClinicalMedicine, 2021, 37, 100957.	3.2	56
218	Food-Derived Bioactive Peptides: A Promising Substitute to Chemosynthetic Drugs Against the Dysregulated Renin-Angiotensin System in COVID-19 Patients. Journal of Biologically Active Products From Nature, 2021, 11, 325-355.	0.1	2
219	Serum biomarkers of cardiovascular complications in COVID-19. Russian Journal of Cardiology, 2021, 26, 4456.	0.4	5

#	Article	IF	Citations
221	Functional ACE2 deficiency leading to angiotensin imbalance in the pathophysiology of COVID-19. Reviews in Endocrine and Metabolic Disorders, 2022, 23, 151-170.	2.6	20
223	Increased Angiotensin-Converting Enzyme 2 and Loss of Alveolar Type II Cells in COVID-19â€"related Acute Respiratory Distress Syndrome. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 1024-1034.	2.5	45
224	Exposure to carbon black nanoparticles during pregnancy aggravates lipopolysaccharide-induced lung injury in offspring: an intergenerational effect. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2021, 321, L900-L911.	1.3	4
225	The pivotal link between ACE2 deficiency and SARS-CoV-2 infection: One year later. European Journal of Internal Medicine, 2021, 93, 28-34.	1.0	40
226	Minireview: What is Known about SUMOylation Among NR4A Family Members?. Journal of Molecular Biology, 2021, 433, 167212.	2.0	3
227	Distinct Regulation of U-ACE2 and P-ACE2 (Urinary and Plasma Angiotensin-Converting Enzyme 2) in a Japanese General Population. Hypertension, 2021, 78, 1138-1149.	1.3	4
228	COVID-19 in pregnancy: What we know from the first year of the pandemic. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2021, 1867, 166248.	1.8	17
229	Research Progress on the Cardiac Injury from ACE2 Targeting in SARS-CoV-2 Infection. Biomolecules, 2021, 11, 196.	1.8	4
230	Covid-19 and Diabetes Mellitus: A Life-Threatening Reciprocal Association. Journal of Biochemical Technology, 2021, 12, 38-43.	0.1	1
231	Lung adenocarcinoma patients have higher risk of SARS-CoV-2 infection. Aging, 2021, 13, 1620-1632.	1.4	14
232	Perspective Adjunctive Therapies for COVID-19: Beyond Antiviral Therapy. International Journal of Medical Sciences, 2021, 18, 314-324.	1.1	24
233	Alternative antibiotic feed additives alleviate pneumonia with inhibiting ACEâ€2 expression in the respiratory system of piglets. Food Science and Nutrition, 2021, 9, 1112-1120.	1.5	5
234	IL-6: Relevance for immunopathology of SARS-CoV-2. Cytokine and Growth Factor Reviews, 2020, 53, 13-24.	3.2	237
235	SARS-CoV-2 and diabetes: New challenges for the disease. Diabetes Research and Clinical Practice, 2020, 164, 108228.	1.1	48
236	Angiotensin converting enzyme-2 as therapeutic target in COVID-19. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2020, 14, 637-639.	1.8	50
237	A suspicious role of interferon in the pathogenesis of SARS-CoV-2 by enhancing expression of ACE2. Signal Transduction and Targeted Therapy, 2020, 5, 71.	7.1	20
238	ACE2 as a potential therapeutic target for pandemic COVID-19. RSC Advances, 2020, 10, 39808-39813.	1.7	21
239	Alternative splicing of ACE2 possibly generates variants that may limit the entry of SARS-CoV-2: a potential therapeutic approach using SSOs. Clinical Science, 2020, 134, 1143-1150.	1.8	23

#	Article	IF	Citations
240	Association of Renin-angiotensin-aldosterone System Inhibitors With Coronavirus Disease 2019 (COVID-19)- Related Outcomes in Korea: A Nationwide Population-based Cohort Study. Clinical Infectious Diseases, 2020, 71, 2121-2128.	2.9	93
241	COVID-19 in Children, Pregnancy and Neonates: A Review of Epidemiologic and Clinical Features. Pediatric Infectious Disease Journal, 2020, 39, 469-477.	1.1	295
242	Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and Mortality Among COVID-19 Patients. American Journal of Therapeutics, 2020, Publish Ahead of Print, .	0.5	10
253	Reninâ€“Angiotensin System Blockers and Adverse Outcomes of Influenza and Pneumonia: A Danish Cohort Study. Journal of the American Heart Association, 2020, 9, e017297.	1.6	7
254	Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China. F1000Research, 2020, 9, 72.	0.8	251
255	Insights into Potential Mechanisms of Injury and Treatment Targets in COVID-19, SARS-Cov-2 Infection. International Journal of Clinical Research & Trials, 2020, 5, .	1.6	5
256	COVID-19: what are the risks in hypertensive patients?. Arterial Hypertension (Russian Federation), 2020, 26, 124-132.	0.1	13
257	Treating the host response to emerging virus diseases: lessons learned from sepsis, pneumonia, influenza and Ebola. Annals of Translational Medicine, 2016, 4, 421-421.	0.7	108
258	The Renin-Angiotensin-Aldosterone System in Coronavirus-19 Disease Pathogenesis: Extracting the Devil in the Details.. SSRN Electronic Journal, 0, , .	0.4	1
259	COVID-19: the endocrine opportunity in a pandemic. Minerva Endocrinologica, 2020, 45, 204-227.	1.7	31
260	Bibliometric analysis of global scientific research on Coronavirus (COVID-19). Medical Journal of the Islamic Republic of Iran, 2020, 34, 51.	0.9	40
261	Possible protective role of 17Î²-estradiol against COVID-19. , 2020, 1, 38-48.		15
262	Hypertension and Electrolyte Disorders in Patients with COVID-19. Electrolyte and Blood Pressure, 2020, 18, 23.	0.6	13
263	2019-nCoV â€“ Towards a 4th generation vaccine. Bioinformation, 2020, 16, 139-144.	0.2	6
264	Why is SARS-CoV-2 infection milder among children?. Clinics, 2020, 75, e1947.	0.6	24
265	Age and genotype dependent erythropoietin protection in COVID-19. World Journal of Stem Cells, 2021, 13, 1513-1529.	1.3	11
266	The Impact of ACE2 Polymorphisms on COVID-19 Disease: Susceptibility, Severity, and Therapy. Frontiers in Cellular and Infection Microbiology, 2021, 11, 753721.	1.8	36
267	Quantifying Renin-Angiotensin-System Alterations in COVID-19. Cells, 2021, 10, 2755.	1.8	21

#	Article	IF	Citations
268	A Pair of â€œACEsâ€• Journal of Dental Research, 2021, , 002203452110475.	2.5	10
269	Regulation of Angiotensin-Converting Enzyme 2: A Potential Target to Prevent COVID-19?. Frontiers in Endocrinology, 2021, 12, 725967.	1.5	14
270	Upregulation of <i>GLE</i>1 and <i>LCP</i>2 Genes in H5N1 Influenza Virus Infected Patients. Advances in Infectious Diseases, 2016, 06, 138-144.	0.0	0
271	Genetic Models. , 2019, , 35-51.		0
272	Estimating COVID-19 Case Fatality Rate in the Middle of the Outbreak: Deadlier than Previously Estimated. SSRN Electronic Journal, 0, , .	0.4	1
273	Novel coronavirus (COVID-19) and its potential G.I. manifestation: A review. Journal of Family Medicine and Primary Care, 2020, 9, 5474.	0.3	1
274	COVID-19 THERAPY: WHAT HAVE WE LEARNED IN 8 MONTHS?. Postepy Mikrobiologii, 2020, 59, 207-225.	0.1	2
275	The Two-Way Switch Role of ACE2 in the Treatment of Novel Coronavirus Pneumonia and Underlying Comorbidities. Molecules, 2021, 26, 142.	1.7	13
276	Study protocol for a multicentre, prospective cohort study of the association of angiotensin II type 1 receptor blockers on outcomes of coronavirus infection. BMJ Open, 2020, 10, e040768.	0.8	7
277	Interplay of COVID-19 and Physiological Dysfunctions. Chinese Journal of Physiology, 2020, 63, 245-249.	0.4	0
278	Acute Kidney Injury and Renal Replacement Therapy in COVID-19 Versus Other Respiratory Viruses: A Systematic Review and Meta-Analysis. Canadian Journal of Kidney Health and Disease, 2021, 8, 205435812110521.	0.6	12
279	Phillyrin for COVID-19 and Influenza Co-infection: A Potential Therapeutic Strategy Targeting Host Based on Bioinformatics Analysis. Frontiers in Pharmacology, 2021, 12, 754241.	1.6	9
281	Diabetes mellitus and COVID-19: current issues of pathogenesis, clinic and therapy. Literature review. Reproductive Endocrinology, 2020, .	0.0	1
283	Combination of C21 and ARBs with rhACE2 as a therapeutic protocol: A new promising approach for treating ARDS in patients with coronavirus infection. Medical Journal of the Islamic Republic of Iran, 2020, 34, 120.	0.9	1
284	Perspectives: potential therapeutic approach with inhalation of ACE2-derived peptides for SARS-CoV-2 infection. American Journal of Clinical and Experimental Immunology, 2020, 9, 73-80.	0.2	1
286	Angiotensin Converting Enzyme-2 (ACE-2) role in disease and future in research. Journal of Lung, Pulmonary & Respiratory Research, 2021, 8, 54-60.	0.3	0
287	ACE2-like carboxypeptidase B38-CAP protects from SARS-CoV-2-induced lung injury. Nature Communications, 2021, 12, 6791.	5.8	32
288	Jing Si Herbal Drink as a prospective adjunctive therapy for COVID-19 treatment: Molecular evidence and mechanisms. Pharmacological Research Modern Chinese Medicine, 2022, 2, 100024.	0.5	5

#	Article	IF	Citations
289	Where all the Roads Meet? A Crossover Perspective on Host Factors Regulating SARS-CoV-2 infection. Journal of Molecular Biology, 2022, 434, 167403.	2.0	2
290	Pathophysiological mechanisms of coronavirus disease (COVID-19) progression and fatal complications in patients with diabetes. PatologÃ¤, 2020, .	0.1	0
292	COVID-19 and Diabetes Mellitus: A Life Threatening Reciprocal Association. Journal of Biochemical Technology, 2021, 12, 104-109.	0.1	0
293	Angiotensin Converting Enzyme-2 (ACE-2) role in disease and future in research. Journal of Lung, Pulmonary & Respiratory Research, 2021, 8, 54-60.	0.3	3
294	DÄ°YABET VE COVID -19. Ankara EÄŸitim Ve AraÅŞtÄ±rma Hastanesi TÄ±p Dergisi, 2022, 54, 471-478.	0.1	0
295	Cytokine storm in COVID-19: from viral infection to immune responses, diagnosis and therapy. International Journal of Biological Sciences, 2022, 18, 459-472.	2.6	65
296	Roles of the gut microbiota in severe SARS-CoV-2 infection. Cytokine and Growth Factor Reviews, 2022, 63, 98-107.	3.2	12
297	The Effects of ATIR Blocker on the Severity of COVID-19 in Hypertensive Inpatients and Virulence of SARS-CoV-2 in Hypertensive hACE2 Transgenic Mice. Journal of Cardiovascular Translational Research, 2022, 15, 38-48.	1.1	3
298	The Impact of COVID-19 On Comorbidities: A Review Of Recent Updates For Combating It. Saudi Journal of Biological Sciences, 2022, 29, 3586-3599.	1.8	53
299	The spike protein of SARS-CoV-2 induces endothelial inflammation through integrin Î±5Î²1 and NF-Î°B signaling. Journal of Biological Chemistry, 2022, 298, 101695.	1.6	74
300	SARS-CoV-2 receptor binding domain fusion protein efficiently neutralizes virus infection. PLoS Pathogens, 2021, 17, e1010175.	2.1	15
301	Kidney Injury in COVID-19: Epidemiology, Molecular Mechanisms and Potential Therapeutic Targets. International Journal of Molecular Sciences, 2022, 23, 2242.	1.8	17
302	Pro-resolving therapies as potential adjunct treatment for infectious diseases: Evidence from studies with annexin A1 and angiotensin-(1-7). Seminars in Immunology, 2022, 59, 101601.	2.7	7
303	Identification of Nifurtimox and Chrysin as Anti-Influenza Virus Agents by Clinical Transcriptome Signature Reversion. International Journal of Molecular Sciences, 2022, 23, 2372.	1.8	3
304	Efficacy of Losartan in Hospitalized Patients With COVID-19â€“Induced Lung Injury. JAMA Network Open, 2022, 5, e222735.	2.8	42
306	The role of microRNAs in COVID-19 with a focus on miR-200c. Journal of Circulating Biomarkers, 2022, 11, 14-23.	0.8	7
307	David versus goliath: ACE2-Fc receptor traps as potential SARS-CoV-2 inhibitors. MAbs, 2022, 14, 2057832.	2.6	7
308	Association of the patterns of use of medications with mortality of COVID-19 infection: a hospital-based observational study. BMJ Open, 2021, 11, e050051.	0.8	6

#	Article	IF	Citations
309	Soluble Human Angiotensin- Converting Enzyme 2 as a Potential Therapeutic Tool for COVID-19 is Produced at High Levels In Nicotiana benthamiana Plant With Potent Anti-SARS-CoV-2 Activity. Frontiers in Plant Science, 2021, 12, 742875.	1.7	11
310	Epipharyngeal Abrasive Therapy Down-regulates the Expression of SARS-CoV-2 Entry Factors ACE2 and TMPRSS2. In Vivo, 2022, 36, 371-374.	0.6	9
312	Angiotensin-converting enzyme 2 as a potential therapeutic target for COVID-19: A review. Journal of Pharmaceutical Analysis, 2022, 12, 215-220.	2.4	12
313	Virus infection induced pulmonary fibrosis. Journal of Translational Medicine, 2021, 19, 496.	1.8	68
316	Emerging Viral Infections and the Potential Impact on Hypertension, Cardiovascular Disease, and Kidney Disease. Circulation Research, 2022, 130, 1618-1641.	2.0	11
317	COVID-19 and diabetes: Association intensify risk factors for morbidity and mortality. Biomedicine and Pharmacotherapy, 2022, 151, 113089.	2.5	36
318	Recombinant ACE2 protein protects against acute lung injury induced by SARS-CoV-2 spike RBD protein. Critical Care, 2022, 26, .	2.5	8
319	Spike-mediated ACE2 down-regulation was involved in the pathogenesis of SARS-CoV-2 infection. Journal of Infection, 2022, 85, 418-427.	1.7	20
320	ACE2-like enzyme B38-CAP suppresses abdominal sepsis and severe acute lung injury. PLoS ONE, 2022, 17, e0270920.	1.1	2
321	An ACE2-IgG4 Fc Fusion Protein Demonstrates Strong Binding to All Tested SARS-CoV-2 Variants and Reduced Lung Inflammation in Animal Models of SARS-CoV-2 and Influenza. Pathogens and Immunity, 2022, 7, 104-121.	1.4	1
322	The Pretreatment of Xiaoqinglong Decoction Alleviates Inflammation and Oxidative Damage and Up-Regulates Angiotensin-Converting Enzyme 2 in Lipopolysaccharide-Induced Septic Acute Lung Injury Rats. Evidence-based Complementary and Alternative Medicine, 2022, 2022, 1-13.	0.5	0
323	Serum Angiotensin II as a Biomarker in COVID-19. Biomarkers in Disease, 2022, , 1-24.	0.0	0
324	Diabetes Mellitus and COVID-19. , 2022, , 29-50.		0
325	An <scp>ACE2</scp> decoy can be administered by inhalation and potently targets omicron variants of <scp>SARSâ€CoV</scp> â€2. EMBO Molecular Medicine, 2022, 14, .	3.3	28
326	Evidence for Interplay Between the Reninâ€“Angiotensin System and Toll-Like Receptor 4 Signaling Pathways in the Induction of Virus-Induced Acute Lung Injury. Journal of Interferon and Cytokine Research, 0, , .	0.5	1
327	COVID-19 outcomes in patients taking cardioprotective medications. PLoS ONE, 2022, 17, e0275787.	1.1	3
328	Mutations in SARS-CoV-2: Insights on structure, variants, vaccines, and biomedical interventions. Biomedicine and Pharmacotherapy, 2023, 157, 113977.	2.5	66
329	When the clock ticks wrong with COVIDâ€19. Clinical and Translational Medicine, 2022, 12, .	1.7	2

#	Article	IF	Citations
330	Is the prognosis of nonâ€hypertensive, COVIDâ€19 patients treated with reninâ€“angiotensinâ€“aldosterone system inhibitors more uncertain?. Physiological Reports, 2022, 10, .	0.7	0
331	SARS-Cov-2 Enfeksiyonu SonrasÄ± GeliÅŸen Romatoid Artrit: Yeni Bir Risk FaktÃ¶rÃ¼ MÃ¼?. Ankara EÄŸitim Ve AraÅŸtÄ±rma Hastanesi TÄ±p Dergisi, 0, , .	0.1	0
332	The Renin Angiotensin System at the Time of COVID-19. , 2023, , 145-156.		0
333	Unusual X chromosome inactivation maintenance in female alveolar type 2 cells is correlated with increased numbers of X-linked escape genes and sex-biased gene expression. Stem Cell Reports, 2023, 18, 489-502.	2.3	4
334	Mouse-Adapted SARS-CoV-2 MA10 Strain Displays Differential Pulmonary Tropism and Accelerated Viral Replication, Neurodissemination, and Pulmonary Host Responses in K18-hACE2 Mice. MSphere, 2023, 8, .	1.3	3
335	Angiotensin II increases respiratory rhythmic activity in the preBÃ¶tzinger complex without inducing astroglial calcium signaling. Frontiers in Cellular Neuroscience, 0, 17, .	1.8	1
337	Transgenic animal models for the functional analysis of ACE2. , 2023, , 491-503.		0
338	Serum Angiotensin II as a Biomarker in COVID-19. Biomarkers in Disease, 2023, , 917-940.	0.0	0
339	The role of the renin-angiotensin-aldosterone system in the development of cardiovascular complications in COVID-19. Pediatrician (St Petersburg), 2023, 14, 98-118.	0.1	0